Research confirms that VEGF and VEGFR are key regulators in lung cancer angiogenesis, serving as primary therapeutic targets for antivascular drug development to inhibit tumor growth, metastasis, and drug resistance. The gene discussed is KDR; the disease is lung carcinoma.